Sarep­ta gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy fails on func­tion — rais­ing se­ri­ous ques­tions about all their drugs

Sarep­ta $SRPT has some ex­plain­ing to do.

Af­ter the mar­ket closed on Thurs­day the con­tro­ver­sial biotech com­pa­ny re­port­ed that their next-gen gene ther­a­py ap­proach to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER